ArticleCureus2026
Oral Contraceptive Use Is Associated With an Increased Risk of Venous Thromboembolism After Lower-Extremity but Not Upper-Extremity Arthroscopic Sports Procedures.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral contraceptive pills (OCPs) are widely used among premenopausal women and have been associated with an increased risk of venous thromboembolism (VTE) due to the prothrombotic effects of estrogen. Although arthroscopic procedures generally carry low postoperative VTE risk, it remains unclear whether OCP use differentially influences thromboembolic complications following upper- and lower-extremity arthroscopic procedures.
methodsThis study used the TriNetX Research Network to query women aged 14-40 who underwent arthroscopic shoulder/elbow or hip/knee/ankle procedures between 2010 and 2025. Patients prescribed OCPs within six months preoperatively to three months postoperatively were compared with those not prescribed OCPs. Exclusion criteria included thrombophilia, prior VTE, hormone replacement therapy, pregnancy, and trauma. Propensity score matching was performed in a 1:1 ratio on demographic and comorbidity variables. Outcomes assessed within 90 days postoperatively included VTE, deep vein thrombosis (DVT), pulmonary embolism (PE), readmission, emergency department (ED) visits, and infection. Results: After propensity score matching, 1,217 patients were included in each upper-extremity cohort and 6,438 patients in each lower-extremity cohort. In the upper-extremity group, OCP use was not associated with an increased risk of VTE (RR: 1.200; 95% CI: 0.520-2.767; p = 0.830), DVT (RR: 1.000; 95% CI: 0.418-2.394; p = 1.000), PE, readmission, ED visits, or infection. In the lower-extremity group, OCP users had a significantly higher risk of VTE (RR: 1.756; 95% CI: 1.199-2.573; p = 0.005) and DVT (RR: 1.714; 95% CI: 1.132-2.597; p = 0.013), but no differences in PE (RR: 1.900; 95% CI: 0.884-4.083; p = 0.137), readmission, ED visits, or infection. Conclusion: In this retrospective propensity-matched database study, OCP use was associated with an increased risk of postoperative VTE and DVT following lower-extremity arthroscopic procedures, but not upper-extremity procedures. These findings should be interpreted in the context of procedural heterogeneity and unavailable perioperative factors, including thromboprophylaxis and postoperative mobilization. Future procedure-specific studies are warranted to better define individualized perioperative VTE risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.